A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.
about
A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@en
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@nl
type
label
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@en
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@nl
prefLabel
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@en
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@nl
P2093
P2860
P356
P1433
P1476
A novel orally available Syk/S ...... B cell lymphoma (BCL) models.
@en
P2093
Mingwu Zheng
Nannan Zhang
P2860
P304
111495-111507
P356
10.18632/ONCOTARGET.22847
P407
P577
2017-12-01T00:00:00Z